Review Article
Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform
Table 2
Cargo loading conditions of encapsulation and backpack approaches.
| Refs. | Loading method | Culture time | Incubation temperature | Drugs/NPs | Drug/NP size (nm) | Drug concentration for loading | Cell carrier type | Final loading amounts (μg drug per million cells) | Cancer type | In vitro/in vivo |
| [70] | Encaps | 5 min | Unknown | Dox/TargetMAG NPs | 50 | 2 μg/mL | T cell | Dox 0.192 | N/A | In vitro | [18] | Encaps. | 2 h | 37°C | Dox/silica NPs | 28.4 | 20 μg/mL | MA | Dox 16.6 | Glioma | In vivo | [72] | Encaps. | 4 h | 37°C | Dox/poly(AAc-co-DSA) NPs | 260 | 13.6 μg/mL | MO | Dox 1.44 | Prostate cancer | In vivo | [67] | Encaps. | 6 h | Unknown | Dox/liposome NPs | 145 | 25 μg/mL | MA | Dox 4.4 | Breast cancer | In vivo | [69] | Encaps. | 8 h | 37°C | PTX/PLGA NPs | 135 | 8 ng/mL | MSC | PTX 1 | Glioma | In vivo | [38] | Encaps. | 12 h | Unknown | PTX/albumin NPs | 100-130 | 200 μL PTX | NE | PTX 18 | Gastric cancer | In vivo | [53] | BP | 20 min | Unknown | Curcumin/chitosan NP-biotin | 377 | 50 μg/mL | MSC | Curcumin 54.73 | Lung cancer | In vivo | [59] | BP | 30 min | 37°C | NSC-87877/liposome NP-PEG | 200 | | T cell | 100 NPs/cell | Prostate tumor | In vivo | [12] | BP | 30 min | 4°C | SN-38/liposome NPs | 340 | Unknown | T cell | SN-38 0.4 | Lymphoma | In vivo | [46] | BP | 30 min | RT | Chlorin e6 | Molecule | 3 μg/mL | RBC | Ce6 molecules on the surface | Breast cancer | In vitro | [51] | BP | 1 h | 37°C | IL-15Sa/nanogel-PEG | 121 | 0.67 μg/mL | T cell | IL-15Sa 7.68 | Melanoma | In vivo | [52] | BP | 1 h | 37°C | Dox/SN-anti-CD90/CD73 | 152.9 | 100 μg/mL | MSC | 1500 NPs/cell | Glioma | In vivo | [24] | BP | 1 h | 4°C | ZnF16Pc/biotin-ferritin | 15-18 | Unknown | RBC | ZnF16Pc molecules on the surface | Glioma | In vivo |
|
|
Encaps. = encapsulation; BP = backpack; RT = room temperature. For other abbreviations, please refer to the abbreviation list.
|